Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Bo Chen, Xiaohong Zhu et al.|Chinese Medical Journal|2023Cited by 40
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Allergy|2024Cited by 30
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Advances in Therapy|2025Cited by 3
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Dermatitis|2025Cited by 1